ly3023414

Carcinoma, Non-small Cell Lung

Eli Lilly and CompanyPhase 2Dormant

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 89/ 100

Competitive context

1206 Active assets in the Carcinoma, Non-small Cell Lung cohort.

Asset / Sponsor	Phase	Rating
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BBB
Necitumumab Jonsson Comprehensive Cancer Center	Phase 3	BBB
Glumetinib Shanghai JMT-Bio Inc.	Phase 3	BBB
Veliparib AbbVie	Phase 3	BBB
d-0316 Betta Pharmaceuticals Co., Ltd.	Phase 2/3	BBB

View all 50 →

Same molecule, other indications

ly3023414 is also rated in:

metastatic prostate carcinomaDormant

B

Indicative ·

57 / 100

pancreatic ductal adenocarcinomaDormant

CCC

Indicative ·

51 / 100

triple-negative breast carcinomaDormant

CCC

Indicative ·

51 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.